

Humira Biosimilars Clinical Trial Insight

<https://marketpublishers.com/r/H0AF231342FEN.html>

Date: October 2016

Pages: 80

Price: US\$ 1,500.00 (Single User License)

ID: H0AF231342FEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.

The Humira stands for Human Monoclonal Antibody in Rheumatoid Arthritis. It is also termed as Adalimumab or D2E7 and is a recombinant Immunoglobulin G1 monoclonal antibody which is specific for tumor necrosis factor alpha (TNF- α). It is a drug designed by the mode of recombinant DNA technology for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. In the rheumatoid arthritis adalimumab has the equivalent efficacy as that of methotrexate.

The chemical and biological components of Humira define it as a TNF inhibiting anti-inflammatory biologic medication. It binds to the TNF- α which leads to the inflammatory response of autoimmune diseases but after the conjugation of Humira it reduces the inflammatory response.

The mechanism of action includes the binding of HUMIRA specifically to TNF- α and renders it, incapable of binding to its receptors on cell surfaces. TNF- α exerts its pro-inflammatory role by binding to its cell surface receptor. When HUMIRA binds to the membrane bound version of TNF- α on TNF- α -producing cells, it can lead to lysis of these TNF- α producing cell in the presence of complement.

TNF- α level is found elevated in the synovial fluids of rheumatoid arthritis. TNF- α is one of the important factors that contribute to the pathology and perpetuation of the inflamed

and destroyed joints in rheumatoid arthritis. Given that rheumatoid arthritis is a complex disease with multiple factors involved, the ability for a monoclonal antibody to neutralize the function of one single cytokine TNF- α and greatly improve the symptoms and progression of rheumatoid arthritis.

It is produced by Abbot Laboratories but originally Humira was emerged from collaboration between Bioresearch Center in Massachusetts (BASF) and the Cambridge Antibody Technologies in the UK. Mid stage clinical trials were so promising that, at the end of 2000, Abbott agreed to buy the BASF Bioresearch Center for US\$ 6.9 Billion. When Humira was launched in 2003, it was the third TNF-alpha antibody to the market. Its US, FDA approval for marketing was achieved on December 31, 2002. In 2012 to 2015 Humira topped the top selling pharmaceutical product lists and in 2015, Humira had topped US\$ 14 Billion of sales globally.

However, its superior dosing schedule and improved toleration over existing therapy enabled it to become the best in class agent. Furthermore, Abbott had a robust development program for Humira and expanded its use to other inflammatory disease such as psoriasis, Crohn's disease, and juvenile idiopathic arthritis. While prescribed to far fewer patients than Lipitor, the high cost of this biological medicine is such that Humira's sales were projected to exceed US\$ 9 Billion.

In December 2014, Indian drug maker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its U.S. price. The generic has been launched under the brand name Exemptia. In January 2016, another Indian drug maker Torrent Pharmaceuticals launched its biosimilar for adalimumab. Torrent's Adfrar would be the second generic biosimilar of adalimumab in the world. In September 2016 the US FDA approved Amgens biosimilar adalimumab-atto sold under the brand name Amjevita.

Contents

1. HUMIRA (ADALIMUMAB) CLINICAL INSIGHT

- 1.1 Clinical Introduction
- 1.2 Company Partnerships & Agreements
- 1.3 Patent Analysis by Indication
- 1.4 Designated Orphan Status by Indication & Country
- 1.5 Brand Names by Country/Region
- Humira Biosimilars Clinical Insight by Company

2. ADALIMUMAB BIOSIMILAR - AET BIOTECH/BIOXPRESS THERAPEUTICS

- 2.1 Clinical Insight
- 2.2 Development Timeline
- 2.3 Phase of Development

3. ADALIMUMAB BIOSIMILAR - ALPHAMAB

- 3.1 Clinical Insight
- 3.2 Development Timeline
- 3.3 Phase of Development

4. ADALIMUMAB BIOSIMILAR - ALTEOGEN/CRISTALIA

- 4.1 Clinical Insight
- 4.2 Phase of Development

5. ADALIMUMAB BIOSIMILAR - AMGEN

- 5.1 Clinical Insight
- 5.2 Development Timeline
- 5.3 Phase of Development

6. ADALIMUMAB BIOSIMILAR - AXZO

- 6.1 Clinical Insight
- 6.2 Phase of Development

7. ADALIMUMAB BIOSIMILAR - BIOCAD

- 7.1 Clinical Insight
- 7.2 Development Timeline
- 7.3 Phase of Development

8. ADALIMUMAB BIOSIMILAR - BIOCND/GENOR BIOPHARMA

- 8.1 Clinical Insight
- 8.2 Development Timeline
- 8.3 Phase of Development

9. ADALIMUMAB BIOSIMILAR - BIOCON/MYLAN

- 9.1 Clinical Insight
- 9.2 Development Timeline
- 9.3 Phase of Development

10. ADALIMUMAB BIOSIMILAR - BIONOVIS/THE INSTITUTO VITAL BRAZIL

- 10.1 Clinical Insight
- 10.2 Development Timeline
- 10.3 Phase of Development

11. ADALIMUMAB BIOSIMILAR - BOEHRINGER INGELHEIM

- 11.1 Clinical Insight
- 11.2 Development Timeline
- 11.3 Phase of Development

12. ADALIMUMAB BIOSIMILAR - CELLTRION

- 12.1 Clinical Insight
- 12.2 Phase of Development

13. ADALIMUMAB BIOSIMILAR - CINNAGEN

- 13.1 Clinical Insight
- 13.2 Phase of Development

14. ADALIMUMAB BIOSIMILAR - COHERUS BIOSCIENCES

- 14.1 Clinical Insight
- 14.2 Development Timeline
- 14.3 Phase of Development

15. ADALIMUMAB BIOSIMILAR - DONG A ST/MEIJI SEIKA PHARMA

- 15.1 Clinical Insight
- 15.2 Development Timeline
- 15.3 Phase of Development

16. ADALIMUMAB BIOSIMILAR - EMD SERONO/MERCK

- 16.1 Clinical Insight
- 16.2 Development Timeline
- 16.3 Phase of Development

17. ADALIMUMAB BIOSIMILAR - FUJIFILM KYOWA KIRIN BIOLOGICS

- 17.1 Clinical Insight
- 17.2 Development Timeline
- 17.3 Phase of Development

18. ADALIMUMAB BIOSIMILAR - GENE TECHNO SCIENCE

- 18.1 Clinical Insight
- 18.2 Phase of Development

19. ADALIMUMAB BIOSIMILAR - HARVEST MOON PHARMACEUTICALS

- 19.1 Clinical Insight
- 19.2 Development Timeline
- 19.3 Phase of Development

20. ADALIMUMAB BIOSIMILAR - HETERO DRUGS

- 20.1 Clinical Insight

20.2 Development Timeline

20.3 Phase of Development

21. ADALIMUMAB BIOSIMILAR - INNOVENT BIOLOGICS

21.1 Clinical Insight

21.2 Development Timeline

21.3 Phase of Development

22. ADALIMUMAB BIOSIMILAR - LG LIFE SCIENCES

22.1 Clinical Insight

22.2 Development Timeline

22.3 Phase of Development

23. ADALIMUMAB BIOSIMILAR - MABXIENCE

23.1 Clinical Insight

23.2 Development Timeline

23.3 Phase of Development

24. ADALIMUMAB BIOSIMILAR - MERIDIAN BIOPHARMACEUTICALS

24.1 Clinical Insight

24.2 Phase of Development

25. ADALIMUMAB BIOSIMILAR - MOMENTA PHARMACEUTICALS

25.1 Clinical Insight

25.2 Development Timeline

25.3 Phase of Development

26. ADALIMUMAB BIOSIMILAR - ONCOBIOLOGICS

26.1 Clinical Insight

26.2 Development Timeline

26.3 Phase of Development

27. ADALIMUMAB BIOSIMILAR - PFIZER

- 27.1 Clinical Insight
- 27.2 Development Timeline
- 27.3 Phase of Development

28. ADALIMUMAB BIOSIMILAR - PLANTPRAXIS

- 28.1 Clinical Insight
- 28.2 Development Timeline
- 28.3 Phase of Development

29. ADALIMUMAB BIOSIMILAR - RELIANCE LIFE SCIENCES

- 29.1 Clinical Insight
- 29.2 Development Timeline
- 29.3 Phase of Development

30. ADALIMUMAB BIOSIMILAR - SAMSUNG BIOEPIS

- 30.1 Clinical Insight
- 30.2 Development Timeline
- 30.3 Phase of Development

31. ADALIMUMAB BIOSIMILAR - SANDOZ

- 31.1 Clinical Insight
- 31.2 Development Timeline
- 31.3 Phase of Development

32. ADALIMUMAB BIOSIMILAR - SHANGHAI HENLIUS BIOTECH

- 32.1 Clinical Insight
- 32.2 Development Timeline
- 32.3 Phase of Development

33. ADALIMUMAB BIOSIMILAR - THERAPEUTIC PROTEINS INTERNATIONAL

- 33.1 Clinical Insight
- 33.2 Phase of Development

34. ADALIMUMAB BIOSIMILAR - ZYDUS CADILA

- 34.1 Clinical Insight
- 34.2 Development Timeline
- 34.3 Phase of Development

35. PATENT LITIGATION ISSUES INVOLVING DEVELOPMENT OF HUMIRA (ADALIMUMAB) BIOSIMILAR

- 35.1 Amgen v/s AbbVie
- 35.2 Coherus v/s AbbVie

List Of Tables

LIST OF TABLES

- Table 1-1: Humira Clinical Trial by Phase of Development
- Table 1-2: Humira - Designated Orphan Status by Indication & Country
- Table 1-3: Humira - Brand Names by Country/Region
- Table 2-1: AET BioTech/BioXpress Therapeutics Adalimumab Biosimilar by Indication & Phase
- Table 3-1: Alphamab Adalimumab Biosimilar by Indication & Phase
- Table 4-1: Alteogen/Cristalia Adalimumab Biosimilar by Indication & Phase
- Table 5-1: Amgen Adalimumab Biosimilar by Indication & Phase
- Table 6-1: Axxo Adalimumab Biosimilar by Indication & Phase
- Table 7-1: Biocad Adalimumab Biosimilar by Indication & Phase
- Table 8-1: BIOCND/Genor Biopharma Adalimumab Biosimilar by Indication & Phase
- Table 9-1: Biocon/Mylan Adalimumab Biosimilar by Indication & Phase
- Table 10-1: Bionovis/The Instituto Vital Brazil Adalimumab Biosimilar by Indication & Phase
- Table 11-1: Boehringer Ingelheim Adalimumab Biosimilar by Indication & Phase
- Table 12-1: Celltrion Adalimumab Biosimilar by Indication & Phase
- Table 13-1: CinnaGen Adalimumab Biosimilar by Indication & Phase
- Table 14-1: Coherus BioSciences Adalimumab Biosimilar by Indication & Phase
- Table 15-1: Dong A ST/Meiji Seika Pharma Adalimumab Biosimilar by Indication & Phase
- Table 16-1: EMD Serono/Merck Adalimumab Biosimilar by Indication & Phase
- Table 17-1: Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar by Indication & Phase
- Table 18-1: Gene Techno Science Adalimumab Biosimilar by Indication & Phase
- Table 19-1: Harvest Moon Pharmaceuticals Adalimumab Biosimilar by Indication & Phase
- Table 20-1: Hetero Drugs Adalimumab Biosimilar by Indication & Phase
- Table 21-1: Innovent Biologics Adalimumab Biosimilar by Indication & Phase
- Table 22-1: LG Life Sciences Adalimumab Biosimilar by Indication & Phase
- Table 23-1: mAbxience Adalimumab Biosimilar by Indication & Phase
- Table 24-1: Meridian Biopharmaceuticals Adalimumab Biosimilar by Indication & Phase
- Table 25-1: Momenta Pharmaceuticals Adalimumab Biosimilar by Indication & Phase
- Table 26-1: Oncobiologics Adalimumab Biosimilar by Indication & Phase
- Table 27-1: Pfizer Adalimumab Biosimilar by Indication & Phase
- Table 28-1: PlantPraxis Adalimumab Biosimilar by Indication & Phase
- Table 29-1: Reliance Life Sciences Adalimumab Biosimilar by Indication & Phase

Table 30-1: Samsung Bioepis Adalimumab Biosimilar by Indication & Phase

Table 31-1: Sandoz Adalimumab Biosimilar by Indication & Phase

Table 32-1: Shanghai Henlius Biotech Adalimumab Biosimilar by Indication & Phase

Table 33-1: Therapeutic Proteins International Adalimumab Biosimilar by Indication & Phase

Table 34-1: Zydus Cadila Adalimumab Biosimilar by Indication & Phase

I would like to order

Product name: Humira Biosimilars Clinical Trial Insight

Product link: <https://marketpublishers.com/r/H0AF231342FEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0AF231342FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970